France-based global healthcare investor has completed the take private of Esperion Therapeutics, a US-based, commercial-stage biopharmaceutical company bringing innovative cardiometabolic and rare/orphan disease therapies to market. The transaction is valued at up to approximately US$1.1bn in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones.
Shareholders receive US$3.16 per share in cash, a 58% premium to Esperion’s closing price on 30 April. They also receive the right to participate in contingent milestone payments of up to US$100m subject to future net sales performance.
“We are excited to acquire a strong biopharmaceutical platform with a portfolio of differentiated products used by cardiologists and primary care physicians to address cardiovascular disease and associated conditions,” said Archimed partner, Justin Bateman.
Founded in 2008, Esperion initially built its business on non-statin bempedoic acid-based drugs Nexletol and Nexlizet, which reduce Low-Density Lipoproteins (LDL, or bad cholesterol) in adults with high blood cholesterol. In March it expanded its portfolio with the acquisition of Enbumyst, the first and only FDA-approved nasal spray for edema associated with congestive heart failure, hepatic disease and renal disease.
Esperion reported net revenue of US$403m in 2025, up 21% over the year. For the full year it reported a net loss of US$22.7m, from a net loss of US$51.7m in 2024.
“This transaction marks a new chapter for Esperion, our employees and the patients and healthcare professionals we serve,” said Esperion CEO, Sheldon Koenig.
Koenig and his team will continue to lead Esperion post-close.
Unitranche debt for the Esperion transaction was provided by Pharmakon Advisors.
Archimed advisors: financial – Moelis & Company; legal – Sidley Austin.
Press release: ARCHIMED Successfully Completes Take-private of Esperion
